Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056833 · ClinicalTrials.gov registry record · Phase 1
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Ronald Buckanovich.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 8
- Study locations
NCT03056833: Completed Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Ronald Buckanovich.
NCT03056833 is a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Ronald Buckanovich. The registered enrollment target is 35 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03056833, a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Ronald Buckanovich.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 8
- Study locations
Study Summary
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.
Primary Outcome
Participants will be observed for the first two treatment cycles (2, 28 day cycles) and maximum tolerated dose will be determined.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG ribociclib
Study Locations (8)
Pennsylvania
- UPMC Hillman Cancer Center Upper St. Clair - Bethel Park
- UPMC Hillman Cancer Center Arnold Palmer at Mountain View - Greensburg
- UPMC Hillman Cancer Center Arnold Palmer Medical at Norwin - Irwin
- UPMC Hillman Cancer Center Arnold Palmer at Mt Pleasant - Mount Pleasant
- University of Pittsburgh Medical Center - Pittsburgh
- UPMC Hillman Cancer Center Passavant (OHA) - Pittsburgh
- UPMC Hillman Cancer Center Washington - Washington
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-06-10 |
| Est. Completion | 2022-08-01 |
| Phase | Phase 1 |
What the finished NCT03056833 record still lists
NCT03056833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT03056833 lists 8 locations in 2 states (Pennsylvania, Michigan).
Frequently Asked Questions
What is clinical trial NCT03056833 about?
NCT03056833 is a clinical study titled "Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer". Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.
What is the current status of trial NCT03056833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-06-10. Estimated completion is 2022-08-01.
What conditions does trial NCT03056833 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma.
What interventions are being tested in trial NCT03056833?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), ribociclib (DRUG).
Who is sponsoring clinical trial NCT03056833?
This trial is sponsored by Ronald Buckanovich, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03056833 being conducted?
This trial has 8 study locations across Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03056833's enrollment target sits among peer trials
35 237th of 322 higher than 81 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI